Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction
Heart failure (HF) is a clinical condition defined by structural and functional abnormalities in the heart that gradually result in reduced cardiac output (HFrEF) and/or increased cardiac pressures at rest and under stress (HFpEF). The presence of asymptomatic individuals hampers HF identification,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/12/7/969 |
| _version_ | 1797433843929579520 |
|---|---|
| author | Federico Ferro Renza Spelat Camilla Valente Paolo Contessotto |
| author_facet | Federico Ferro Renza Spelat Camilla Valente Paolo Contessotto |
| author_sort | Federico Ferro |
| collection | DOAJ |
| description | Heart failure (HF) is a clinical condition defined by structural and functional abnormalities in the heart that gradually result in reduced cardiac output (HFrEF) and/or increased cardiac pressures at rest and under stress (HFpEF). The presence of asymptomatic individuals hampers HF identification, resulting in delays in recognizing patients until heart dysfunction is manifested, thus increasing the chance of poor prognosis. Given the recent advances in metabolomics, in this review we dissect the main alterations occurring in the metabolic pathways behind the decrease in cardiac function caused by HF. Indeed, relevant preclinical and clinical research has been conducted on the metabolite connections and differences between HFpEF and HFrEF. Despite these promising results, it is crucial to note that, in addition to identifying single markers and reliable threshold levels within the healthy population, the introduction of composite panels would strongly help in the identification of those individuals with an increased HF risk. That said, additional research in the field is required to overcome the current drawbacks and shed light on the pathophysiological changes that lead to HF. Finally, greater collaborative data sharing, as well as standardization of procedures and approaches, would enhance this research field to fulfil its potential. |
| first_indexed | 2024-03-09T10:22:40Z |
| format | Article |
| id | doaj.art-d95cbb67666e48029cebe878a259de5c |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-09T10:22:40Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-d95cbb67666e48029cebe878a259de5c2023-12-01T21:56:35ZengMDPI AGBiomolecules2218-273X2022-07-0112796910.3390/biom12070969Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection FractionFederico Ferro0Renza Spelat1Camilla Valente2Paolo Contessotto3Department of Medical, Surgery and Health Sciences, University of Trieste, 34125 Trieste, ItalyNeurobiology Sector, International School for Advanced Studies (SISSA), 34136 Trieste, ItalyDepartment of Molecular Medicine, University of Padova, 35122 Padova, ItalyDepartment of Molecular Medicine, University of Padova, 35122 Padova, ItalyHeart failure (HF) is a clinical condition defined by structural and functional abnormalities in the heart that gradually result in reduced cardiac output (HFrEF) and/or increased cardiac pressures at rest and under stress (HFpEF). The presence of asymptomatic individuals hampers HF identification, resulting in delays in recognizing patients until heart dysfunction is manifested, thus increasing the chance of poor prognosis. Given the recent advances in metabolomics, in this review we dissect the main alterations occurring in the metabolic pathways behind the decrease in cardiac function caused by HF. Indeed, relevant preclinical and clinical research has been conducted on the metabolite connections and differences between HFpEF and HFrEF. Despite these promising results, it is crucial to note that, in addition to identifying single markers and reliable threshold levels within the healthy population, the introduction of composite panels would strongly help in the identification of those individuals with an increased HF risk. That said, additional research in the field is required to overcome the current drawbacks and shed light on the pathophysiological changes that lead to HF. Finally, greater collaborative data sharing, as well as standardization of procedures and approaches, would enhance this research field to fulfil its potential.https://www.mdpi.com/2218-273X/12/7/969metabolomicsheart failure with reduced ejection fractionheart failure with preserved ejection fractionmicrobiotabiomarkers |
| spellingShingle | Federico Ferro Renza Spelat Camilla Valente Paolo Contessotto Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction Biomolecules metabolomics heart failure with reduced ejection fraction heart failure with preserved ejection fraction microbiota biomarkers |
| title | Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction |
| title_full | Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction |
| title_fullStr | Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction |
| title_full_unstemmed | Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction |
| title_short | Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction |
| title_sort | understanding how heart metabolic derangement shows differential stage specificity for heart failure with preserved and reduced ejection fraction |
| topic | metabolomics heart failure with reduced ejection fraction heart failure with preserved ejection fraction microbiota biomarkers |
| url | https://www.mdpi.com/2218-273X/12/7/969 |
| work_keys_str_mv | AT federicoferro understandinghowheartmetabolicderangementshowsdifferentialstagespecificityforheartfailurewithpreservedandreducedejectionfraction AT renzaspelat understandinghowheartmetabolicderangementshowsdifferentialstagespecificityforheartfailurewithpreservedandreducedejectionfraction AT camillavalente understandinghowheartmetabolicderangementshowsdifferentialstagespecificityforheartfailurewithpreservedandreducedejectionfraction AT paolocontessotto understandinghowheartmetabolicderangementshowsdifferentialstagespecificityforheartfailurewithpreservedandreducedejectionfraction |